These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 33305478)

  • 1. Switching between biologics in severe asthma patients. When the first choice is not proven to be the best.
    Papaioannou AI; Fouka E; Papakosta D; Papiris S; Loukides S
    Clin Exp Allergy; 2021 Feb; 51(2):221-227. PubMed ID: 33305478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
    Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
    Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
    Carpagnano GE; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Quarato CMI; Foschino Barbaro MP
    Ther Adv Respir Dis; 2020; 14():1753466620929231. PubMed ID: 32482128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Biologics in Asthma.
    McGregor MC; Krings JG; Nair P; Castro M
    Am J Respir Crit Care Med; 2019 Feb; 199(4):433-445. PubMed ID: 30525902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of biologics in personalized asthma care.
    Watchorn D; Holguin F
    Expert Rev Clin Immunol; 2021 Dec; 17(12):1301-1309. PubMed ID: 34767743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological treatments in childhood asthma.
    Nieto-García A; Nieto-Cid M; Mazón-Ramos Á
    Curr Opin Allergy Clin Immunol; 2024 Jun; 24(3):114-121. PubMed ID: 38567842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologics for Severe Asthma: Treatment-Specific Effects Are Important in Choosing a Specific Agent.
    Krings JG; McGregor MC; Bacharier LB; Castro M
    J Allergy Clin Immunol Pract; 2019; 7(5):1379-1392. PubMed ID: 31076056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.
    Liu MC; Chipps B; Munoz X; Devouassoux G; Bergna M; Smith SG; Price RG; Galkin DV; Azmi J; Mouneimne D; Albers FC; Chapman KR
    Respir Res; 2021 May; 22(1):144. PubMed ID: 33971856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omalizumab and mepolizumab in the landscape of biological therapy for severe asthma in children: how to choose?
    Giovannini M; Mori F; Barni S; de Martino M; Novembre E
    Ital J Pediatr; 2019 Nov; 45(1):151. PubMed ID: 31779657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential of biologics for the treatment of asthma.
    Pelaia G; Vatrella A; Maselli R
    Nat Rev Drug Discov; 2012 Dec; 11(12):958-72. PubMed ID: 23197041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promises and challenges of biologics for severe asthma.
    Tan R; Liew MF; Lim HF; Leung BP; Wong WSF
    Biochem Pharmacol; 2020 Sep; 179():114012. PubMed ID: 32389637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologics and Bronchial Thermoplasty for severe refractory asthma treatment: From eligibility criteria to real practice. A cross-sectional study.
    Menzella F; Galeone C; Ruggiero P; Bagnasco D; Catellani C; Facciolongo N
    Pulm Pharmacol Ther; 2020 Feb; 60():101874. PubMed ID: 31857207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe asthma: When to resort to biological agents.
    Tenero L; Rossignoli S; Piacentini G
    Pediatr Allergy Immunol; 2020 Feb; 31 Suppl 24():37-39. PubMed ID: 32017206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biologics for oral corticosteroid-dependent asthma.
    Yılmaz İ
    Allergy Asthma Proc; 2020 May; 41(3):151-157. PubMed ID: 32375958
    [No Abstract]   [Full Text] [Related]  

  • 15. The clinical profile of benralizumab in the management of severe eosinophilic asthma.
    Menzella F; Lusuardi M; Galeone C; Facciolongo N; Zucchi L
    Ther Adv Respir Dis; 2016 Dec; 10(6):534-548. PubMed ID: 27612492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [SWITCHING BIOLOGICS LED TO GOOD CONTROL IN SEVERE CHILDHOOD ASTHMA: A CASE REPORT].
    Imai A; Takizawa T; Sato K; Inoue T; Nishida Y; Yagi H; Arakawa H
    Arerugi; 2019; 68(7):869-873. PubMed ID: 31406083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologics for paediatric severe asthma: trick or TREAT?
    Saglani S; Bush A; Carroll W; Cunningham S; Fleming L; Gaillard E; Gupta A; Murray C; Nagakumar P; Paton J; Roberts G; Seddon P; Sinha I
    Lancet Respir Med; 2019 Apr; 7(4):294-296. PubMed ID: 30824361
    [No Abstract]   [Full Text] [Related]  

  • 18. Biological therapy management from the initial selection of biologics to switching between biologics in severe asthma.
    Yılmaz İ; Paçacı Çetin G; Arslan B; Şeker S; Bozkurt Yılmaz HE; Aktaş Yapıcı E; Köylüce S; Açar E
    Tuberk Toraks; 2023 Mar; 71(1):75-93. PubMed ID: 36912412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Home Self-Administration of Biologics - A German Survey among Omalizumab-Treated Patients with Severe Asthma and their Treating Physicians.
    Timmermann H; Mailänder C
    Pneumologie; 2020 Feb; 74(2):103-111. PubMed ID: 31935761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pediatric asthma: guidelines-based care, omalizumab, and other potential biologic agents.
    Huffaker MF; Phipatanakul W
    Immunol Allergy Clin North Am; 2015 Feb; 35(1):129-44. PubMed ID: 25459581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.